Table 2.
Outcomes data at 24 h and days 2–5 following chemotherapy.
| Outcomes | Control Group (n = 346) |
Olanzapine Group (n = 383) |
|---|---|---|
| Overall nausea control from day 0 to 51 | ||
| Significant nausea | 41.3% | 27.7% |
| None or mild nausea | 56.1% | 72.1% |
| Missing | 2.6% | 0.03% |
| Overall vomiting control from days 0 to 52 | ||
| Yes | 7.5% | 4.2% |
| No | 89.3% | 95.8% |
| Missing | 3.2% | 0.03% |
| Acute nausea3 | ||
| Significant nausea | 28.3% | 19.6% |
| None or mild nausea | 69.4% | 80.4% |
| Missing | 2.3% | 0.0% |
| Acute vomiting4 | ||
| Yes | 3.2% | 2.1% |
| No | 94.5% | 97.9% |
| Missing | 2.3% | 0.0% |
| Delayed nausea5 | ||
| Significant nausea | 32.4% | 21.9% |
| None or mild nausea | 64.4% | 77.3% |
| Missing | 3.2% | 0.8% |
| Delayed vomiting6 | ||
| Yes | 5.2% | 3.6% |
| No | 91.6% | 96.1% |
| Missing | 3.2% | 0.03% |
| Mean duration of nausea (hours; 95%CI)7 | 23.5 (17.4–29.6) | 10.0 (7.1–12.9) |
| Patients requiring rescue medication over all cycles of chemotherapy8 | 40.0% | 32.1% |
| Complete cycle response from day 0 to day 59 | 32.4% | 41.8% |
1P = 0.001, 2P = 0.066, 3P = 0.011, 4P = 0.36, 5P = 0.006, 6P = 0.32, 7P < 0.001, 8P = 0.041, 9P = 0.03. Based on the Hochberg step-up test procedure, the threshold for statistical significance was P < 0.005.